A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin amyloidosis with polyneuropathy. Polyneuropathy stages and disability scores were ...
Hereditary transthyretin amyloidosis (hATTR) is a rare inherited disorder that gets worse over time. It often affects the nerves, heart, liver, and kidneys, but it can also affect other organs.
Hereditary transthyretin-mediated amyloidosis (hATTR) is a type of amyloidosis, which is a group of diseases where abnormal proteins (amyloids) build up and damage areas of the body. When the amyloids ...
Amvuttra is a subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein. The Food and Drug Administration (FDA) has approved Amvuttra ...
Please provide your email address to receive an email when new articles are posted on . Wainua has received regulatory approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis.
The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in ...
– Vutrisiran Met All 18-Month Secondary Endpoints, Including Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), Gait Speed, Nutritional Status and Overall ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) approved ...
Treatment with the investigational CRISPR-Cas9 gene-editing therapy, NTLA-2001, led to rapid responses in patients with transthyretin (TTR) amyloidosis with cardiomyopathy (ATTR-CM), interim phase 1 ...
"Alterations in axonal membrane and channel function occur early in the disease course, prior to discernable large fibre involvement, and has the potential to be used as an early biomarker of ...
The life expectancy for transthyretin (ATTR) amyloidosis varies from person to person. Your age, overall health, and primary symptoms all play a role. Transthyretin amyloidosis (ATTR) is a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results